The Management of Pulmonary Hypertension in Infants and Children
A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Pulmonary and Sleep Medicine".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 785
Special Issue Editors
Interests: pulmonary hypertension; cardiac dysfunction; echocardiographic assessment; biomarker; congenital diaphragmatic hernia; bronchopulmonary dysplasia
2. Center for Rare Diseases Bonn, Division of Congenital Malformations, University of Bonn, 53127 Bonn, Germany
Interests: pulmonary hypertension; cardiac dysfunction; echocardiographic assessment; biomarker; congenital diaphragmatic hernia; bronchopulmonary dysplasia
Special Issue Information
Dear Colleagues,
Pulmonary hypertension (PH) is one of the major contributors to short- and long-term morbidity and mortality in critically ill infants and children. In particular, infants and children with underlying congenital or acquired cardiovascular and pulmonary diseases are at risk when PH is diagnosed, with the need for long-term pharmaceutical treatment.
Therefore, the diagnosis and treatment of PH play an important role in its management in infants and children. Different diagnostic approaches, including biomarker profiles, echocardiographic assessments, and strategies such as multi-omic profiling, are becoming increasingly available and popular for the diagnosis of PH. Furthermore, multiple pharmaceutical treatment strategies have been evaluated in recent years in infants and children, offering insights into treatment effects and drug profiles.
This Special Issue will provide innovative and informative data on recent advantages in PH management, including new aspects of diagnosis and treatment of PH in pediatric populations. This Special Issue will focus on offering insights from retrospective and prospective clinical research of modern PH management to improve infant’s and children’s future medical care.
Dr. Lukas Schroeder
Dr. Florian Kipfmueller
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- biomarker profiles
- echocardiographic assessment
- multi-omic profiling
- pharmaceutical treatment
- infants
- children
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Meconium aspiration syndrome, Hypoxic Ischemic Encephalopathy and Therapeutic Hypothermia - A Recipe for Severe Pulmonary Hypertension?
Authors: Deepika Sankaran; Jessa Li; Satyan Lakshminrusimha
Affiliation: Division of Neonatology, University of California, Davis, Sacramento, California, USA 95817
Abstract: Hypoxic ischemic encephalopathy (HIE) is the leading cause of mortality among term newborns globally. Infants born through meconium-stained amniotic fluid are at risk of developing meconium aspiration syndrome (MAS) and HIE. Simultaneous occurrence of MAS and HIE is a perilous combination for newborns due to risk of persistent pulmonary hypertension of the newborn (PPHN). Moreover, therapeutic hypothermia (TH) which is the current standard of care for management of HIE may increase the pulmonary vascular resistance (PVR) and worsen PPHN. Infants with MAS and HIE require close cardiorespiratory and hemodynamic monitoring for PPHN. Therapeutic strategies including oxygen supplementation, ventilation, use of surfactant, inhaled nitric oxide and other pulmonary vasodilators, and systemic vasopressors play a critical role in the management of PPHN in MAS, HIE and TH. While TH reduces death or disability in infants with HIE, infants with MAS and HIE undergoing TH need close hemodynamic monitoring for PPHN.
Title: right ventricle remodeling in Pulmonary Hypertension
Authors: Zengkong Dai
Affiliation: Kaohsiung Medical University, Kaohsiung, Taiwan